Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Yamazaki

Showing results (231-240 of 252) with videos related to

Pageof 26
Sort By:
JCO Precision Oncology|June 21, 2023
Clinical Validation of Plasma-Based Genotyping for <i>RAS</i> and <i>BRAF</i> V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA SubstudyYu Aoki, Yoshiaki Nakamura, Tadamichi Denda, et al.
JAMA|April 18, 2023
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical TrialJun Watanabe, Kei Muro, Kohei Shitara, et al.
Nature Medicine|September 16, 2024
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumorsYoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database studyKazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
Journal of Cancer Research and Clinical Oncology|May 27, 2022
NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)Takeshi Kajiwara, Tomohiro Nishina, Akio Nakasya, et al.
The Oncologist|November 15, 2018
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal CancerYoshihiko Fujita, Masataka Taguri, Kentaro Yamazaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-JapanYoshiaki Nakamura, Kristiyana Kaneva, Christine Lo, et al.
Nature Medicine|February 12, 2024
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Kei Muro, Jun Watanabe, et al.
International Journal of Clinical Oncology|November 4, 2025
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancerYusuke Kinugasa, Kay Uehara, Kensei Yamaguchi, et al.
Gut|July 12, 2014
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium studyRavit Geva, Loredana Vecchione, Konstantinos T Kalogeras, et al.
Pageof 26

Showing results (231-240 of 252) with videos related to

Sort By:
Pageof 26
JCO Precision Oncology|June 21, 2023
Clinical Validation of Plasma-Based Genotyping for <i>RAS</i> and <i>BRAF</i> V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA SubstudyYu Aoki, Yoshiaki Nakamura, Tadamichi Denda, et al.
JAMA|April 18, 2023
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical TrialJun Watanabe, Kei Muro, Kohei Shitara, et al.
Nature Medicine|September 16, 2024
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumorsYoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database studyKazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
Journal of Cancer Research and Clinical Oncology|May 27, 2022
NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)Takeshi Kajiwara, Tomohiro Nishina, Akio Nakasya, et al.
The Oncologist|November 15, 2018
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal CancerYoshihiko Fujita, Masataka Taguri, Kentaro Yamazaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-JapanYoshiaki Nakamura, Kristiyana Kaneva, Christine Lo, et al.
Nature Medicine|February 12, 2024
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Kei Muro, Jun Watanabe, et al.
International Journal of Clinical Oncology|November 4, 2025
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancerYusuke Kinugasa, Kay Uehara, Kensei Yamaguchi, et al.
Gut|July 12, 2014
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium studyRavit Geva, Loredana Vecchione, Konstantinos T Kalogeras, et al.
Pageof 26